Author: admin

Jason Kelly, PhD Co-founder, CEOGinkgo Bioworks Most people still picture science as a person in a white coat, pipette in hand. That image is stubbornly accurate. Even in 2025—after decades of lab robots, high‑throughput screening, and cloud computing—the overwhelming majority of experimental work is still done by hand at the lab bench. The result is that the “limiting reagent” for progress on everything from climate‑friendly fuels to cancer therapeutics is not ideas or data analysis. It is the slow, manual generation of high‑quality experimental data. That bottleneck is why autonomous laboratories should matter to everyone, not just to scientists. When…

If you live with celiac disease or gluten sensitivity, you know the grocery store can feel like a minefield. One of the most common questions I hear in my clinic is: “Are egg noodles gluten free?” It is a fair question. After all, eggs are naturally gluten-free. Many people hope that the “egg” in the name means they are safe for a gluten-free diet. Unfortunately, the answer for traditional varieties is a firm no. Standard egg noodles are made from a mixture of eggs and wheat flour. Because wheat is the primary source of gluten, these noodles are unsafe for…

This webinar will be hosted live and available on-demand February 17-18, 2026 11:30 AM – 3:30 PM ET Biomarkers are critical tools for detecting and monitoring disease, understanding pathogenic mechanisms, and tracking therapeutic responses. From proteomic profiling to AI-based algorithms, scientists leverage new techniques and technologies to investigate biomarkers of different pathologies and discover improved treatment avenues. In this symposium brought to you by The Scientist, experts will share how they use established and emerging biomarker discovery approaches to uncover new insights into disease biology.       James Zou, PhD Associate Professor Biomedical Data Science Stanford University Gold Sponsor Silver…

Nick Edwards, PhD, CEO of Potato, has a “burning desire” to speed up scientific discovery. In an interview with GEN, he explained how Potato’s AI “scientist,” named Tater, recently replicated a main discovery from his PhD research investigating circuit specificity of the brain’s reward center.1 As a graduate student, Edwards recalls that experiments could span five to six hours, while troubleshooting flaws in protocols would take weeks. In contrast, Tater was able to take unpublished raw data, complete a statistical analysis, generate code to reproduce results, and create figures to summarize findings within a few hours. “Tater found some relevant…

Credit: Ozgu Arslan/Getty Images An artificial intelligence (AI)-based large language model (LLM) was able to match clinician suggestions for simple, early stage hepatocellular carcinoma but was less able to match clinical recommendations for more complex, later stage cases. As reported in PLOS Medicine, for the earlier stage cases the treatment suggested by the LLM was linked to better survival, but for late stage cases the closer the treatment matched the AI suggestion the poorer the patient’s outcome was. “Liver cancer… is common worldwide, and choosing the right treatment can be difficult because it depends on both the cancer stage and…

Alzheimer’s disease risk may be largely attributable to a single gene.Image credit:© iStock.com, seb_raAlzheimer’s disease, the most common cause of dementia, has complex genetic and environmental causes. A new study that combined data from four large analyses of the disease has suggested that one single gene may influence as many as nine out of ten cases.1 Identifying Harmful Gene VariantsScientists have linked the APOE gene, which codes for a protein that carries cholesterol in the bloodstream, to Alzheimer’s disease since the 1990s, but the new data suggest that the field has underestimated the gene’s impact.The APOE gene has three common…

Co-founder Hanadie Yousef to step down as CEO as company gears up for more clinical trials of drugs designed to restore tissue function. Longevity biotech Juvena Therapeutics has secured $33.5 million in a Series B financing as it moves deeper into clinical development and expands a pipeline built around regenerative biologics. Drawing on insights from human biology, the Redwood City–based company is developing engineered proteins designed to restore tissue function, with a focus on neuromuscular and age-related diseases. Juvena, which raised $41 million in a Series A funding round in 2022, is building a pipeline of biologics addressing chronic muscle…

Credit: KTSDESIGN/SCIENCE PHOTO LIBRARY/Getty Images An AI tool that uses detailed information from nearly all countries in the world has identified bespoke, national policy areas that could offer the greatest benefits in improving cancer survival. The Global Health Predictor Insights Tool has been made freely available online and could help governments plan their cancer healthcare systems more effectively. Machine learning highlighted national improvements in areas such as economic strength, radiotherapy accessibility and universal health coverage that could have the greatest impact on cancer outcomes. The novel approach, published in the in the Annals of Oncology, could help prioritize resources to…

The results of preclinical research headed by a team at Karolinska Institutet have indicated how T cells that play a role in the immune system’s reaction to the common Epstein-Barr virus (EBV) can also cross-react with a protein in the brain, ultimately contributing to multiple sclerosis (MS). The team said the study provides new insight into the long-suspected link between EBV and MS. “Our results provide mechanistic evidence that immune responses to EBV can directly damage the brain in MS,” said Olivia Thomas, PhD, assistant professor at the Department of Clinical Neuroscience at Karolinska Institutet. “It is a complex neurological…

Nuclera, the biotechnology company accelerating drug discovery by providing rapid, easy access to functional proteins through its benchtop eProtein Discovery™ System, today announced that it has completed the first installations of eProtein Discovery in Asia, with systems now operational at the Department of Pharmacy and the Department of Chemistry at the National Taiwan University (NTU) College of Medicine and the Center for Bioscience and Biotechnology and Department of Chemical Engineering at the National Cheng Kung University (NCKU). These installations represent Nuclera’s first commercial sales in Asia, marking a major milestone in the Company’s global expansion strategy.Following the installation of eProtein…